PRP Science signs an exclusive sales contract for PLLA filler "Olivia" in 6 European countries. South Korea in the planning.

- The third PLLA filler in the world to be certified as a European CE.Which got the domestic product certification after Sculptra.

PRP SCIENCE, a filler manufacturer, announced that it has signed exclusive sales agreements with six European countries for OLIDIA on Monday, a PLLA filler approved by the U.S. Food and Drug Administration (FDA). The ministry of Food and Drugs approved the safety and effectiveness of the drug in July last year and plans to launch a sales agreement in South Korea starting this year.

OLIDIA, developed by PRP SCIENCE with domestic technology, promotes collagen production to improve wrinkles and takes effect after four to six weeks. Because 80% is composed of balanced particles, it can better maintain the three-dimensional feeling and injection feeling is also excellent. Its biggest advantage is that the injection water and suspension time can be up to 30 minutes faster, so it can be treated on the same day.

OLIDIA is the second Korean filler to receive product certification and the third in the world to receive European CE certification following Sculptra, a representative PLLA filler developed by Sanofi-Aventis, a global pharmaceutical company

Clinical trials that were certified in Korea were conducted at two university hospitals in Korea. The temporary improvement effect and safety of Nasolabial Fold were compared with 109 cases of OLIDIA and Sculptra certificates. The results demonstrated that new tissue was formed around the injection site of the filler and facilitated collagen production, confirming that OLIDIAhas the same physical and chemical properties and decomposition prime factors as Sculptra.

According to PRP SCIENCE, the filler market will be positioned as a polymer market in the next few years, and the market of PLLA filler, which is a biodegradable polymer, will greatly expand. This can be seen in the growing domestic and global market share of PLLA filler Secultra.

OLIDIA has now signed exclusive sales contracts with six European countries and expects to push ahead with domestic sales agreements from January, he said. "We signed contracts worth more than 50 billion won with China over the past five years after obtaining the certification from the National Medical Products Administration of China. "We have signed contracts worth more than 30 billion won in The South American market for the past five years since our product was certified by The Brazilian Health Supervision Agency ANVISA. We are looking forward to future sales."

'In addition to OLIDIA, which is the latest launch, we will also develop products for the anti-aging market, such as toners, in due course,' the person said. "Our goal is to differentiate ourselves from other companies and become the world's second-largest polymer filler manufacturer by focusing on polymer products," he said.